Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to evaluate the efficacy of intense pulsed light in treating dry eye caused by meibomian gland dysfunction and make a comparison between the traditional treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| traditional treatment group | Other | Subjects in this group are treated by tobramycin and dexamethasone ophthalmic ointment qn and artificial tears qid. |
|
| IPL treatment group | Experimental | Subjects in this group are treated with 3 cycles of intense pulsed light of 4 weeks interval and artificial tears qid. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| intense pulsed light | Device | Intense pulse light (IPL) has been used in dermatology practices for several years as a treatment for rosacea and acne.IPL uses Xenon flashlamp to emit wavelengths of light from 400 to 1200nm. When placed on the light, a filter restricts the wavelength to the visible light range of *500nm.In 2007-2008, an IPL treatment technology-the Diamond Q4 by DermaMed Solutions-was specifically configured to our specifications with the goal of stimulating secretion of normal meibum via skin treatment effects on the meibomian glands. It was discovered that dry eye patients are better positioned for gland expression, as IPL seems to liquefy the abnormal viscous meibum and dilate the glands. |
| Measure | Description | Time Frame |
|---|---|---|
| Ocular Surface Disease Index (OSDI) | normal value：<13 abnormal value：≥ 13 | through study completion,an average of 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| The concentrations of inflammatory cytokines such as IL-1、IL-6 and IL-8 | through study completion,an average of 6 months | |
| breakup time of tear film （BUT） | normal value：>10s abnormal value：≤ 10s |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015352 | Dry Eye Syndromes |
| ID | Term |
|---|---|
| D007766 | Lacrimal Apparatus Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D062325 | Intense Pulsed Light Therapy |
| D014031 | Tobramycin |
| ID | Term |
|---|---|
| D010789 | Phototherapy |
| D013812 | Therapeutics |
| D009328 | Nebramycin |
| D007612 | Kanamycin |
| D000617 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Tobramycin and Dexamethasone Ophthalmic Ointment | Drug |
|
| through study completion,an average of 6 months |
| Corneal Fluorescein Stain(CFS) | through study completion,an average of 6 months |
| Eyelid ester discharge ability score | through study completion,an average of 6 months |
| Eyelid ester trait ratings | through study completion,an average of 6 months |
| Aminoglycosides |
| D006027 | Glycosides |
| D002241 | Carbohydrates |